Finance Foggle

Trump Administration Weight Loss Drug Pilot: Medicare & Medicaid Coverage for Ozempic, Wegovy in 2026-2027 - GLP-1 Costs, State Participation & Obesity Treatment Policy Key Takeaways Medicare and Medicaid will launch voluntary pilot coverage for GLP-1 weight loss drugs ( Ozempic ,  Wegovy ,  Zepbound ,  Mounjaro ) starting 2026-2027 . The 5-year experiment requires participating plans to include structured diet/exercise coaching alongside medication . Current rules exclude weight loss drug coverage under Medicare, with limited Medicaid exceptions (13 states) . Annual costs per patient range $5,000-$7,000, projected Medicare spending could hit $35B by 2034 . Internal Trump administration conflict exists: CMS’s  Mehmet Oz  supports coverage, while HHS Secretary  Robert F. Kennedy Jr.  criticizes costs . The Policy Shift Hits Like a Diner Coffee at 3 AM Medicare, Medicaid plans to experiment with covering weight loss drugs The Trump administration...

  Key Takeaways Coca-Cola's potential switch  to cane sugar follows political pressure but faces  economic hurdles  . Price disparity : High-fructose corn syrup costs  $0.35/lb  vs. cane sugar at  $1.01/lb , nearly triple. Farm impact : Eliminating corn syrup could wipe out  $5.1B in U.S. farm revenue  . Health equivalence : The FDA states  no nutritional difference  exists between the sweeteners . Consumer cost : Mexican Coke (cane sugar) costs  over 60% more  than U.S. corn-syrup versions . The President’s Truth Social Bombshell President Trump fired a post into the digital ether. He claimed Coca-Cola agreed to dump high-fructose corn syrup for "REAL Cane Sugar" in U.S. products. The announcement hit like a barstool declaration, loud, abrupt, short on details. Coca-Cola’s response? A terse nod to "new innovative offerings." No confirmation. No timeline. Just corporate speak wrapped in a question mark. The disconnect betw...

  Key Takeaways RFK Jr.'s MAHA Agenda : HHS Secretary Robert F. Kennedy Jr. aims for all Americans to use wearables within 4 years to combat chronic disease through real-time health tracking . Behavioral Motivation : Wearables like  Fitbit  and  Apple Watch  boost physical activity and help manage conditions like diabetes by providing instant feedback on glucose/heart rates . Privacy Risks : Data breaches (e.g., 23andMe hack) and insurance misuse (e.g., premium hikes based on tracked vitals) are major concerns . Accuracy Gaps : Skin tone variations and motion artifacts can skew heart rate/sleep data; devices aren’t FDA-approved for diagnosis . Cost Barriers : Continuous glucose monitors cost $100–$300/month, creating accessibility issues for low-income groups . RFK Jr.’s Wearable Vision: Health Revolution or Privacy Pitfall? So yeah, Health Secretary Robert F. Kennedy Jr. dropped this big plan last week—like, he wants  every single American  strapped i...